Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04486911 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 27, 2020
Last Update Posted : August 2, 2022
|
Sponsor:
Shengjing Hospital
Information provided by (Responsible Party):
Caigang Liu, Shengjing Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 1, 2026 |
| Estimated Study Completion Date : | December 30, 2026 |